Psoriatic Arthritis– Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
-1.jpg)
Psoriatic arthritis (PsA) is a chronic
inflammatory autoimmune disease associated with joints and the place where
tendons and ligaments are connected to bone and usually occurs in combination
with a skin disorder called psoriasis. Enthesitis is one of the most common
characteristic features. Other clinical features, including swelling joints,
itchy-painful red patches, silvery while building up dead skin cells, and PsA
also affect the sacroiliac joint of the pelvic and spine, causing stiffness in
and around the neck and back. The exact cause of psoriatic arthritis is still
unknown. It starts emerging in individuals aged 30 to 50 and can begin as early
as childhood. Both genders are equally at the same risk level. The genetic
epidemiology of PsA also supports its unique status. PsA has been associated
with human leukocyte antigen (HLA) class 1 alleles as opposed to the class 2
alleles associated with RA. Extra-articular manifestations of PsA are also
different from those of RA. In particular, rheumatoid nodules are absent.
Rheumatoid factor, detected in more than 80% of patients with RA, may be seen
in about 13% of patients with PsA.
- The prevalence of Psoriatic arthritis
(PsA) ranges from 0.05% to 0.25% in the general population and 6% to 41%
in psoriasis patients.
Thelansis’s “Psoriatic Arthritis (PsA) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Psoriatic Arthritis (PsA) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Psoriatic Arthritis across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Psoriatic Arthritis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment